Published on 8 Jun 2023 on Zacks via Yahoo Finance
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
Baudax Bio, Inc. BXRX announced additional positive data from its phase II study of BX1000, which is used as a neuromuscular blockade (“NMB”) in patients undergoing elective surgery. The efficacy of the NMB is assessed by analyzing its electromyography (“EMG”).
Additional analysis of EMG of BX1000 confirmed that administration of the higher dose of the long-acting drug showed a benefit profile that compares favorably with the current standard-of-care neuromuscular blocking agent, rocuronium.
The stock of the company jumped 4.4% on Wednesday, following the positive news.